ClinicalTrials.Veeva

Menu
H

Hadassah University Hospital | Hadassah Medical Centre - Hematology Clinical Research

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenalidomide
Ataluren
Zimura
Sialic Acid
Dexamethasone
GED-0301
Rucaparib
KSI-301
Amphotericin B
Aflibercept

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 83 total trials

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

The purpose of this trial is to find out if epcoritamab, also known as EPKINLY™ and GEN3013, is safe and works well as treatment for patients with di...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

The purpose of this study is to determine how participants with metastatic castration-resistant prostate cancer, and evidence of a homologous recombi...

Active, not recruiting
Metastatic Castration Resistant Prostate Cancer
Drug: Abiraterone acetate or Enzalutamide or Docetaxel
Drug: Rucaparib

The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not...

Enrolling
Melanoma
Drug: Nivolumab + Relatlimab
Drug: rHuPH20

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatmen...

Active, not recruiting
Metastatic Cholangiocarcinoma
Unresectable Cholangiocarcinoma
Drug: Gemcitabine
Drug: Cisplatin

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for treatment of recurrent Lung Cancer .

Enrolling
Recurrent Lung Cancer
Lung Cancer
Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for...

Enrolling
Amyotrophic Lateral Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pem...

Active, not recruiting
Unresectable Melanoma
Metastatic Melanoma
Drug: Pembrolizumab
Drug: IO102-IO103

It is a phase one study with dose escalation and safety CART in BCMA- Expressing Multiple Myeloma and AL amyloidosis Patients

Enrolling
Dose Escalation and Safety
Drug: NXC-201 (formerly HBI0101)

A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON s...

Enrolling
Becker Muscular Dystrophy
Drug: Placebo
Drug: Sevasemten 10 mg

The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBC...

Enrolling
Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Lenalidomide
Drug: Tafasitamab

The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with a...

Active, not recruiting
Stargardt's Macular Dystrophy
Drug: Sham
Drug: avacincaptad pegol

Trial sponsors

H
Celgene logo
PTC Therapeutics logo
AbbVie logo
E
A
Incyte logo
I
Kodiak Sciences logo
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems